Approval · Notice of Compliance 29947 · 2023
POLIVY: Notice of Compliance 29947
Issued January 20, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29947
- Date
- January 20, 2023
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Fulfillment of conditions 4, 5, 6, 7, 9, 10, 11, and 12 from the Letter of Undertaking dated June 16, 2020
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| POLIVY | Not yet assigned | — |
Medicinal ingredients
- POLATUZUMAB VEDOTIN 30 MG per VIAL
- POLATUZUMAB VEDOTIN 140 MG per VIAL